MIT cancer biologists have shown how resistance to cisplatin arises

Proteasome inhibitors prevent cisplatin-induced mitochondrial release of apoptosis-inducing factor and markedly ameliorate cisplatin nephrotoxicity.

Secondary mutations as a mechanism of cisplatin resistance in BRCA2-mutated cancers

Prognostic factors for response to cisplatin-based chemotherapy in advanced cervical carcinoma: a Gynecologic Oncology Group Study.

Mechanism of Cisplatin-Resistance in BRCA2-Related Ovarian Cancers

Sensitization of squamous cell carcinoma to cisplatin induced killing by natural agents.

Meta-analysis finds cisplatin improves post-operative survival in patients with non-small lung cancer.

ASCO 2008 meeting: Cetuximab plus platinum chemotherapy agents effective treatment for lung cancer.

Also for head and neck cancers.

A phase I and pharmacokinetic study of paclitaxel poliglumex and cisplatin in patients with advanced solid tumors.

Cisplatin-Based Chemotherapy Improves Survival in Non-Small Cell Lung Cancer - National Cancer Institute

Meta-Analysis Suggests Cisplatin Superior to Carboplatin for Advanced NSCLC - NCI Clinical Trial result

Long-Term Data Support Cisplatin-Based Chemoradiation for Cervical Cancer - NCI Clinical Trial result

Cisplatin-Based Chemotherapy Improves Survival in Non-Small Cell Lung Cancer - Clinical trial result

Evaluation of DNA damage in vivo induced by combined application of cisplatin and sevoflurane.

Cisplatin- versus carboplatin-based chemotherapy in first-line treatment of advanced non-small-cell lung cancer

Antitumor activity of the combination of synthetic retinoid ST1926 and cisplatin in ovarian carcinoma models.

Cisplatin-mediated impairment of mitochondrial DNA metabolism inversely correlates with glutathione levels.

Other web resources about cisplatin